NeuroLucent is a therapeutic drug development company focused on patented breakthrough compounds targeting Alzheimer’s disease. It has licensed the patents and intellectual property of Rosalind Franklin University of Medicine and Science, developed by Grace "Beth" Stutzmann, Associate Professor, and Principal Investigator and CSO of the Company. Through its novel and breakthrough research, the University has identified the key metabolic process that destroys neurons and synaptic function, and ultimately, memories. NeuroLucent’s patented compounds target and normalize the function of this dysregulated signaling channel and restores neuronal activity, and preserves neuronal plasticity and dendritic structure. This strategy effectively halts the progression of Alzheimer's disease and allows the brain’s natural processes to restore function.